Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Peng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0569-9001; OpenAlex author ID A5100396111. Sources: OpenAlex.

Their work

Papers
30 (first author 4, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 5 papers · 2014: 3 papers · 2015: none · 2016: 2 papers · 2017: 4 papers · 2018: 6 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 2 papers

Papers 30

  1. Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.34334↗
  2. Inflammatory/immune-suppressive microenvironment characteristics of pancreatic cancer patients with Shi-Re syndrome identified by extracellular vesicle long RN… Last author DOI 10.53388/tmr20230111002↗
  3. Circulating EVs long RNA-based subtyping and deconvolution enable prediction of immunogenic signatures and clinical outcome for PDAC. Last author DOI 10.1016/j.omtn.2021.08.017↗
  4. A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and Cancer Cells Regulates Pancreatic Cancer Metastasis. Last author DOI 10.1158/0008-5472.can-20-0256↗
  5. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. Last author DOI 10.1136/gutjnl-2019-318860↗
  6. Functions and clinical implications of exosomes in pancreatic cancer. Last author DOI 10.1016/j.bbcan.2018.11.001↗
  7. Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2019.01.015↗
  8. Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer. Co-author DOI 10.1002/cam4.1848↗
  9. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2018.04.137↗
  10. Effects of baicalein on pancreatic cancer stem cells via modulation of sonic Hedgehog pathway. Co-author DOI 10.1093/abbs/gmy045↗
  11. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. Co-author DOI 10.1177/0300060518800588↗
  12. TAM Infiltration Differences in "Tumor-First" and " ZHENG-First" Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer. First author DOI 10.1177/1534735418771193↗
  13. Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. Co-author DOI 10.3390/ijms19061768↗
  14. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. First author DOI 10.1016/j.pan.2017.08.072↗
  15. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine… Co-author DOI 10.1038/srep45194↗
  16. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3233/cbm-170231↗
  17. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. Co-author PMID 28123853↗
  18. Ski modulate the characteristics of pancreatic cancer stem cells via regulating sonic hedgehog signaling pathway. Co-author DOI 10.1007/s13277-016-5461-8↗
  19. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. First author DOI 10.18632/oncotarget.6450↗
  20. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Co-author DOI 10.1038/srep05911↗
  21. MicroRNA expression in salivary supernatant of patients with pancreatic cancer and its relationship with ZHENG. Co-author DOI 10.1155/2014/756347↗
  22. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0096177↗
  23. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting… Co-author DOI 10.1016/j.molonc.2012.10.011↗
  24. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Co-author DOI 10.1053/j.gastro.2013.07.048↗
  25. Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. First author DOI 10.1371/journal.pone.0070334↗
  26. MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy. Co-author DOI 10.4161/auto.26463↗
  27. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Co-author DOI 10.5754/hge13498↗
  28. miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. Co-author DOI 10.1002/jcb.24200↗
  29. High intensity focused ultrasound treatment for patients with advanced pancreatic cancer: a preliminary dosimetric analysis. Co-author DOI 10.3109/02656736.2012.713541↗
  30. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Co-author DOI 10.3109/02656736.2010.525588↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiqiang Meng · 20 shared papers, 2011–2023 · strength 1.58
  2. Zhen Chen · 22 shared papers, 2011–2021 · strength 1.50
  3. Lianyu Chen · 10 shared papers, 2011–2021 · strength 0.62
  4. Chao Qu · 7 shared papers, 2014–2021 · strength 0.58
  5. Ling Mei Qian · 5 shared papers, 2019–2021 · strength 0.56
  6. Yawen Geng · 4 shared papers, 2017–2023 · strength 0.48
  7. Luming Liu · 8 shared papers, 2011–2018 · strength 0.44
  8. Shulin Yu · 4 shared papers, 2019–2021 · strength 0.43
  9. Chien‐shan Cheng · 3 shared papers, 2018–2023 · strength 0.38
  10. Luming Liu · 5 shared papers, 2013–2018 · strength 0.35
  11. Shenglin Huang · 3 shared papers, 2019–2021 · strength 0.32
  12. Song Gao · 5 shared papers, 2012–2018 · strength 0.32
  13. Yalei Zhang · 2 shared papers, 2021–2023 · strength 0.31
  14. Wen‐Bin Zou · 2 shared papers, 2020–2023 · strength 0.28
  15. Hao Chen · 4 shared papers, 2014–2018 · strength 0.28
  16. Hao Chen · 4 shared papers, 2014–2018 · strength 0.28
  17. Liping Zhuang · 3 shared papers, 2013–2023 · strength 0.26
  18. Zhouyu Ning · 2 shared papers, 2017–2023 · strength 0.26
  19. Jie Fan · 4 shared papers, 2013–2021 · strength 0.24
  20. Yuchen Li · 2 shared papers, 2020–2021 · strength 0.21
  21. Kun Wang · 5 shared papers, 2011–2017 · strength 0.20
  22. Qi Qi · 3 shared papers, 2014–2018 · strength 0.20
  23. Chenyue Zhang · 2 shared papers, 2016–2021 · strength 0.19
  24. Changjing Huang · 1 shared paper, 2023 · strength 0.19
  25. Shu-Lin Yu · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.